JP2013519364A5 - - Google Patents

Download PDF

Info

Publication number
JP2013519364A5
JP2013519364A5 JP2012552395A JP2012552395A JP2013519364A5 JP 2013519364 A5 JP2013519364 A5 JP 2013519364A5 JP 2012552395 A JP2012552395 A JP 2012552395A JP 2012552395 A JP2012552395 A JP 2012552395A JP 2013519364 A5 JP2013519364 A5 JP 2013519364A5
Authority
JP
Japan
Prior art keywords
sequence
seq
polypeptide
amino acid
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012552395A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013519364A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/051958 external-priority patent/WO2011098520A1/en
Publication of JP2013519364A publication Critical patent/JP2013519364A/ja
Publication of JP2013519364A5 publication Critical patent/JP2013519364A5/ja
Pending legal-status Critical Current

Links

JP2012552395A 2010-02-10 2011-02-10 アゴニストdr5結合ポリペプチド Pending JP2013519364A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30317310P 2010-02-10 2010-02-10
US61/303,173 2010-02-10
US30859910P 2010-02-26 2010-02-26
US61/308,599 2010-02-26
PCT/EP2011/051958 WO2011098520A1 (en) 2010-02-10 2011-02-10 Agonist dr5 binding polypeptides

Publications (2)

Publication Number Publication Date
JP2013519364A JP2013519364A (ja) 2013-05-30
JP2013519364A5 true JP2013519364A5 (enExample) 2014-03-27

Family

ID=43877025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012552395A Pending JP2013519364A (ja) 2010-02-10 2011-02-10 アゴニストdr5結合ポリペプチド

Country Status (31)

Country Link
US (2) US9120855B2 (enExample)
EP (1) EP2534176A1 (enExample)
JP (1) JP2013519364A (enExample)
KR (1) KR20130031241A (enExample)
CN (1) CN102884083A (enExample)
AR (1) AR080158A1 (enExample)
AU (1) AU2011214355B2 (enExample)
BR (1) BR112012019924A2 (enExample)
CA (1) CA2789251A1 (enExample)
CL (1) CL2012002217A1 (enExample)
CO (1) CO6561836A2 (enExample)
CR (1) CR20120415A (enExample)
CU (1) CU24133B1 (enExample)
EA (1) EA201201114A1 (enExample)
GE (1) GEP20146176B (enExample)
GT (1) GT201200236A (enExample)
IL (1) IL221289A0 (enExample)
MA (1) MA34053B1 (enExample)
MX (1) MX2012009328A (enExample)
MY (1) MY156337A (enExample)
NI (1) NI201200134A (enExample)
NZ (1) NZ601582A (enExample)
PE (1) PE20121703A1 (enExample)
PH (1) PH12012501613A1 (enExample)
SG (1) SG183210A1 (enExample)
TN (1) TN2012000393A1 (enExample)
TW (1) TWI480051B (enExample)
UA (1) UA106900C2 (enExample)
UY (1) UY33222A (enExample)
WO (1) WO2011098520A1 (enExample)
ZA (1) ZA201205864B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012057288A1 (ja) 2010-10-29 2012-05-03 第一三共株式会社 新規抗dr5抗体
GB201118359D0 (en) 2011-10-25 2011-12-07 Univ Sheffield Pulmonary hypertension
US20150056204A1 (en) * 2012-03-28 2015-02-26 Amgen Inc. Dr5 receptor agonist combinations
WO2014159562A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
WO2015100409A2 (en) * 2013-12-26 2015-07-02 Tufts University Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
JP6176683B2 (ja) * 2014-01-10 2017-08-09 学校法人帝京平成大学 組換え偏性嫌気性グラム陽性菌
RU2017129236A (ru) * 2015-01-26 2019-03-07 Макродженикс, Инк. Мультивалентные молекулы, содержащие dr5-связывающие домены
CN104826121A (zh) * 2015-02-11 2015-08-12 嘉兴学院 肿瘤靶向基因递送系统及其应用
KR20250017305A (ko) * 2015-07-16 2025-02-04 인히브릭스 바이오사이언스, 인크. 다가 및 다중특이적 dr5-결합 융합 단백질
KR102791773B1 (ko) * 2015-10-30 2025-04-03 갤럭시 바이오테크, 엘엘씨 사멸 수용체 4 및 사멸 수용체 5에 결합하는 매우 강력한 항체
NO2768984T3 (enExample) 2015-11-12 2018-06-09
KR101926834B1 (ko) * 2017-03-21 2018-12-07 동아에스티 주식회사 항-dr5 항체 및 그의 용도
CN111699197B (zh) * 2017-11-13 2024-08-23 克雷森多生物制剂有限公司 结合cd137的单结构域抗体
US20190234933A1 (en) * 2018-02-01 2019-08-01 Genadam Therapeutics, Inc. Compositions and assays
CN117285643A (zh) 2022-06-16 2023-12-26 清华大学 一种相变调节套件及其用途
IL317689A (en) 2022-07-15 2025-02-01 Boehringer Ingelheim Int Binding molecules for cancer treatment
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
EP4653468A1 (en) * 2023-01-17 2025-11-26 Suzhou Youthen Biotechnology Co., Ltd Dr5 domain variant and use thereof
TW202515917A (zh) * 2023-06-29 2025-04-16 美商奧迪希治療公司 抗trailr2抗原結合蛋白及其用途
WO2025206402A1 (ja) * 2024-03-29 2025-10-02 株式会社沖縄Ukami養蚕 アフリカ豚熱ワクチン産生組換えエリ蚕及びその利用

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
ATE165113T1 (de) 1992-05-08 1998-05-15 Creative Biomolecules Inc Mehrwertige chimäre proteine anologe und verfahren zu deren anwendungen
EP0651805B1 (en) 1992-07-17 2006-12-13 Dana Farber Cancer Institute Method of intracellular binding of target molecules
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
WO1994029457A2 (en) 1993-06-09 1994-12-22 Unilever N.V. Process for producing fusion proteins comprising scfv fragments by a transformed mould
US6091639A (en) 1993-08-27 2000-07-18 Kabushiki Kaisha Toshiba Non-volatile semiconductor memory device and data programming method
CA2183667A1 (en) 1994-02-22 1995-08-24 Wayne A. Marasco Nucleic acid delivery system, method of synthesis and uses thereof
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
AU7298398A (en) 1996-11-19 1998-06-10 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6670453B2 (en) 1997-10-27 2003-12-30 Unilever Patent Holdings B.V. Multivalent antigen-binding proteins
BR9907241A (pt) 1998-01-26 2000-10-17 Unilever Nv Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
ID26964A (id) 1998-02-19 2001-02-22 Xcyte Therapies Inc Komposisi dan metode untuk pengaturan pengaktifan limfosit
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
DK1144616T4 (da) 1999-01-19 2009-03-30 Unilever Nv Fremgangsmåde til fremstilling af antistoffragmenter
ES2270893T3 (es) 1999-12-24 2007-04-16 Genentech, Inc. Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos.
US20020004587A1 (en) 2000-04-11 2002-01-10 Genentech, Inc. Multivalent antibodies and uses therefor
EP1278767A4 (en) 2000-04-12 2003-11-12 Principia Pharmaceutical Corp ALBUMIN FUSED PROTEINS
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
WO2002057445A1 (en) 2000-05-26 2002-07-25 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US6741957B1 (en) 2000-07-21 2004-05-25 Daimlerchrysler Corporation Analytical tire model for vehicle durability and ride comfort analysis
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2003014960A2 (en) 2001-08-03 2003-02-20 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
CN100506277C (zh) 2001-11-01 2009-07-01 Uab研究基金会 肿瘤坏死因子相关细胞凋亡诱导配体受体的选择性抗体和其它治疗剂的联合体系
KR100599789B1 (ko) 2001-12-03 2006-07-12 삼성에스디아이 주식회사 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
CA2471116A1 (en) 2001-12-21 2003-07-03 Serge Muyldermans Method for cloning of variable domain sequences
CA2471645A1 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン.ヴェー. 安定化単一ドメイン抗体
EP1576179B1 (en) 2002-11-27 2010-09-15 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
AU2003285578B2 (en) 2002-12-03 2010-07-15 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
CN100343304C (zh) 2002-12-31 2007-10-17 尼克塔治疗亚拉巴马公司 水解稳定的马来酰亚胺封端的聚合物
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
DK1639011T3 (da) 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
CA2535550A1 (en) 2003-08-12 2005-03-03 William M. Yarbrough Treatment for acne vulgaris and method of use
US20060263353A1 (en) 2003-08-20 2006-11-23 Lawson Alastair D G Methods for obtaining antibodies
GB0328261D0 (en) * 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
KR20070010046A (ko) 2004-04-06 2007-01-19 제넨테크, 인크. Dr5 항체 및 그의 용도
WO2005114187A2 (en) 2004-04-23 2005-12-01 The United States Of America As Represented By Thesecretary, Department Of Health And Human Services Methods and compositions for diagnosing aids and other diseases and conditions involving immune system activation
MXPA06014795A (es) 2004-06-21 2007-03-26 Univ Washington Anticuerpos contra el virus del nilo occidental y usos terapeuticos y profilacticos de los mismos.
US20060008601A1 (en) 2004-06-25 2006-01-12 Zeik Douglas B Flexible laminate having an integrated pressure release valve
WO2006008548A2 (en) 2004-07-22 2006-01-26 Erasmus University Medical Centre Rotterdam Binding molecules
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
RU2007117752A (ru) 2004-10-13 2008-11-20 Аблинкс Н.В. (Be) Нанотела (nanobodies тм) против бета-амилоида и полипептидов, содержащих бета-амилоид, для лечения нейродегенеративных заболеваний, таких как болезнь альцгеймера
WO2006040154A2 (en) 2004-10-14 2006-04-20 Dublin City University Prokaryotic two hybrid system
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
GB2424983A (en) 2005-04-07 2006-10-11 Autoliv Dev Seatbelt pretensioner control system
EP2479191A3 (en) 2005-05-18 2013-03-13 Ablynx N.V. Improved nanobodiesTM against tumor necrosis factor-alpha
ES2852423T3 (es) 2005-05-20 2021-09-13 Ablynx Nv NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
WO2007112940A2 (en) 2006-03-31 2007-10-11 Ablynx N.V. Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
AU2007237501A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. DP-78-like nanobodies
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
US20100113339A1 (en) 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
CN101528767A (zh) 2006-10-11 2009-09-09 埃博灵克斯股份有限公司 以基本不依赖pH的方式结合血清蛋白的氨基酸序列、包括其的化合物、及其用途
WO2008066854A2 (en) 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
CN101611056A (zh) 2006-12-05 2009-12-23 埃博灵克斯股份有限公司 能够结合于血清蛋白的肽
JP5302519B2 (ja) 2007-08-03 2013-10-02 倉敷紡績株式会社 ヒトパピローマウイルスを検出するためのプライマーセット及びプローブ
WO2009030285A1 (en) 2007-09-07 2009-03-12 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same

Similar Documents

Publication Publication Date Title
JP2013519364A5 (enExample)
JP2022079549A5 (enExample)
JP2017535257A5 (enExample)
JP2009225799A5 (enExample)
IL266756A (en) Human monoclonal antibodies that bind to MASP 2 and suppress MASP-dependent complement activation, methods for their production and uses
JP2014526898A5 (enExample)
JP2018521638A5 (enExample)
JP2011046732A5 (enExample)
JP2010533498A5 (enExample)
FI3487882T3 (fi) Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja
JP2017514461A5 (enExample)
JP2013056885A5 (enExample)
JP2019501883A5 (enExample)
JP2020500538A5 (enExample)
JP2018506961A5 (enExample)
JP2017519759A5 (enExample)
JP2013545455A5 (enExample)
SI2753646T1 (en) Anti-CD40 antibodies, uses and methods
HRP20201375T1 (hr) ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
JP2015535828A5 (enExample)
JP2016507523A5 (enExample)
JP2013534515A5 (ja) 受容体型チロシンキナーゼc−Metに対する抗体
JP2014205674A5 (enExample)
JP2012525829A5 (enExample)